Ramazan Kaan KAVAKLI

Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı Ve Hastalıkları Anabilim Dalı

Araştırma alanları: Sağlık Bilimleri, Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Hematoloji, Çocuk Sağlığı ve Hastalıkları, Onkoloji, Temel Tıp Bilimleri, Tıbbi Biyoloji, Pediatrik Hematoloji

<p>CURRICULUM VITAE (2025) <span style="color: red;">KAAN KAVAKLI, M.D.</span></p><p><br></p><p><strong>HOME ADDRESS:</strong></p><p>SOYAK - Mavişehir Sitesi B bölgesi. 6523. Sokak B-4 Blok No: 21 Daire:12 Kat:3 Karşıyaka - Izmir – TR-35550 - Turkey</p><p>E-mail: <a href="mailto:kaan.kavakli61@gmail.com" rel="noopener noreferrer" target="_blank">kaan.kavakli61@gmail.com</a></p><p><strong>Mobile and Whats Appl (24 hours): + 90 542 432 87 38</strong></p><p><br></p><p><strong>BUSINESS ADDRESS:</strong></p><p>Ege University Children’s Hospital Dept. Pediatric Hematology University Street TR-35100 Bornova- Izmir- Turkey</p><p>Phone: + 90 232 390 10 17</p><p>Fax: + 90 232 388 99 00</p><p>E-mail: <a href="mailto:kaan.kavakli@ege.edu.tr" rel="noopener noreferrer" target="_blank">kaan.kavakli@ege.edu.tr</a></p><p><br></p><p>DATE OF BIRTH : March 3^rd, 1961 (Turkey)</p><p>MARITAL STATUS: Married</p><p>LANGUAGES SPOKEN: English, Turkish</p><p><strong>INTERESTED FIELDS: Hemostasis and Thrombosis, Congenital Bleeding Disorders, Hemophilia treatment, Gene Therapy,</strong></p><p><strong>International Clinical Trials (Phases 1-2-3-4), </strong></p><p><br></p><p><strong><u>WORK EXPERIENCE </u></strong></p><p><br></p><p><strong>11/2021 – Today Professor of Pediatrics and Pediatric Hematology</strong></p><p>11/2018 – 11/2021 Chairman, Dept. Pediatrics Ege University Medical Faculty, Izmir, Turkey</p><p>07/2002-11-2018 Professor of Pediatrics and Pediatric Hematology</p><p>2002-2006: Chairman, Hemophilia Subcommittee of Turkish Hematology Association</p><p>1998-Today: Chairperson, Research Ethics Committee of Ege University Hospital</p><p>1998-Today: Chairman, Dept. Pediatric Hematology, Medical School of Ege University</p><p><strong>9/1996-3/1997: Working and visiting in Angelo Bianchi Bonomi Hemophilia and Thrombosis center in Milano, Italy.</strong></p><p>6/1995-Today: Pediatric Hematologist, Dept. Pediatrics, Ege University Hospital</p><p>1/1991-4/1991: “Visiting Residency” in Pediatrics, University of Wisconsin, Madison, USA</p><p>11/1986- 10/1991: Residency in Pediatrics, Ege University Hospital, Izmir</p><p>8/1985-11/1986: General Practitioner, Ayvalik State Hospital,Turkey</p><p>3/1984- 8/1985: General Practitioner, Military Hospital, Ağri, Turkey</p><p>7/1983- 3/1884: General Practitioner, Savur, Mardin, Turkey</p><p><strong><u> </u></strong></p><p><strong><u> </u></strong></p><p><strong><u> </u></strong></p><p><strong><u>NGO TASKS:</u></strong></p><p><strong><u> </u></strong></p><p>General Director 2005 – Today <strong> </strong>Hemophilia Federation (of Turkey)</p><p><br></p><p><strong>Director 2016 – Today Thrombosis Hemostasis and Angiology Association (of Turkey)</strong></p><p><br></p><p>Director <strong> </strong>1996 – Today<strong> </strong>Ege Hemophilia Society</p><p><strong><u> </u></strong></p><p><strong><u> </u></strong></p><p><strong><u> </u></strong></p><p><strong><u>EDUCATIONAL BACKGROUND</u></strong></p><p><u> </u></p><p>7/2002: Certified for Professorship in Pediatrics and Faculty Member of Ege University Medical Faculty</p><p>11/1995: Certified for Ass. Professorship in Pediatrics.</p><p>2/1992- 5/ 1995: Certified in Pediatric Hematology, Ege University Hospital</p><p>11/1986- 10/1991: Certified in Pediatrics</p><p>6/1983: Graduated from Ege University Medical School with degree of doctor of medicine.</p><p><br></p><p><br></p><p><strong><u> </u></strong></p><p><strong><u>PUBLICATIONS</u> </strong> (2025)</p><p><br></p><p>Publications indexed by PubMed: 200</p><p><br></p><p>Publication in an indexed by Web of Science: 300</p><p><br></p><p><strong>Citations determined by SCI: 4200</strong></p><p><br></p><p><strong>H – index 29</strong></p><p><br></p><p><br></p><p><em><u> </u></em></p><p><em><u> </u></em></p><p><em><u> </u></em></p><p><em><u> </u></em></p><p><em><u> </u></em></p><p><em><u> </u></em></p><p><strong>SOME SELECTED PUBLICATIONS</strong></p><p><br></p><ol><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Cuker A, <strong><u>Kavakli K</u></strong>, Frenzel L, et al. Gene therapy with Fidanococog Fitoparvovec in adult haemophilia-B. <strong>New England J Medicine</strong></li></ol><p>2024; 391: 1108-1118.</p><ol><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Young G, Srivastava A, <strong><u>Kavakli K,</u></strong> et al. Efficacy and safety of Fitusuran for inhibitor patients. ATLAS-INH study. <strong>Lancet</strong> 2023; 29 Mart, 2023.</li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Srivastava A, Rangarajan S, <strong><u>Kavakli K,</u></strong> et al. Fitusuran prophylaxis in people with HA or HB without inhibitors. <strong>Lancet Haematology</strong> 2023, 29 Mart 2023.</li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Shapiro AD, Anghaikuri P, Astermark J, Benson G, <strong>Kavakli K</strong>, et al. Subcutaneous concizumab prohylaxis in HA and HA/HB with inhibitors: phase-2 trail results. <strong>Blood</strong> 2019; 134: 1973-1982.</li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Mancuso EM, Male C, Kenet G, <strong>Kavakli K,</strong> et al. Prohylaxis in children with hemophilia in an evolving treatment landscape. <strong>Haemophilia</strong> 2021; 27: 889-896.</li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Peyvandi F, Mannucci PM,<strong>Kavakli K</strong>, et al. A randomised trial of factor FVIII and neutralizing antibodies in Hemophilia A. (Sippet Study<strong>). N Engl J Med 2016; 374: 2054-2064.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli K</u><strong>, </strong>Smith L, et al.<strong> </strong>Once weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe hemophilia B. <strong>Haemophilia 2016; 29 Jan 2016; 1-8.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli K</u>, Yang G, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free rFVIII product: results from a randomized trial (LEOPOLD II<strong>). J Thromb Haemost 2015; 13: 360-369.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Tiede A, Brand B, Fischer R, <u>Kavakli K.</u> Enhancing the PK properties of rFVIII: first in-human trial of glycol-PEGlated rFVIII in patients with hemophilia-A. <strong>J Thromb Haemost 2013; 11: 670-678</strong>.</li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Kavakli K, et al. Micronucleus evaluation for determining the chromosomal breakages after radionuclide synovectomy in patients with hemophilia. Ann <strong>Nucl Med 2012; 26: 41-46.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Leisinger C, Gringeri A, Antmen B, <u>Kavakli K</u>, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. <strong>N Engl J N Med 2011; 365: 1684-1692.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Akin M, <u>Kavakli K</u>. Laboratory Diagnosis and management of vonWillebrand disease in Turkey: Izmir experience. <strong>Semin Thromb Hemost 2011; 37: 581-586.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli K,</u> et al. The value of early treatment in patients with hemophilia and inhibitors. <strong>Haemophilia 2010; 16: 487-94.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli et al</u>. Long-term evaluation of chromosomal breakages after radioisotope synovectomy for treatment of target joints in patients with hemophilia. <strong>Haemophilia 2010; 16: 474-78.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli K</u>, Aydoğdu S, Taner M, et al. Radioisotope synovectomy with Rhenium 186 in hemophilic synovitis for elbows, ankles and shoulders. <strong>Haemophilia 2008 14; 518-523.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Fidanci ID, <u>Kavakli K</u>, Ucar C, et al. Factor 8 gene mutation profile of Turkish hemophilia A patients with inhibitors. <strong>Blood Coagul Fibrinolysis 2008; 19: 383-388</strong>.</li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Unuvar A, <u>Kavakli K</u>, Baytan B, et al. Low-dose immune tolerance induction for pediatric hemophilia patients with factor VIII inhibitors. <strong>Haemophilia 2008; 14: 315-322.</strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span>Astermark J, Oldenburg J, Carlson J, Pavlova A, <u>Kavakli K</u>, Berntorp E, Lefvert AK.</li></ol><p>Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. <strong>Blood 2006 108; 3739-3745. </strong></p><ol><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli K</u>, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G; NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. <strong>Thromb Haemost. 2006; 95: 600-605. </strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli K</u>, Aydogdu S, Omay SB, Duman Y, Taner M, Capaci K, Memis A, Balkan C, Karapinar D. Long-term evaluation of radioisotope synovectomy with Yttrium 90 for chronic synovitis in Turkish haemophiliacs: Izmir experience. <strong>Haemophilia 2006;12:28-35. </strong></li><li data-list="ordered"><span class="ql-ui" contenteditable="false"></span><u>Kavakli K</u>, Aledort LA. Circumcision and Haemophilia: a perspective. <strong>Haemophilia 1998; 4 : 1</strong>-3.</li></ol>

Yayınlar

• Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER (2026)
• Evaluation of Oral and Dental Health Findings in Children with Hemophilia (2025)
• HTRS2025.O8C.3 Alfa-PROTECT: A Phase 3, Open-Label Study to Evaluate the Safety of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to <12 Years With Severe Hemophilia A (2025)
• HTRS2025.P2.54 Corticosteroid Experience With Fidanacogene Elaparvovec in Adults With Moderately Severe or Severe Hemophilia B: Results From the Phase 3 BENEGENE-2 Gene Therapy Trial (2025)
• HTRS2025.P2.77 Once every two weeks administration of Mim8 prophylaxis for patients with hemophilia A with or without inhibitors: Interim safety and efficacy analysis of the FRONTIER4 open-label extension study (2025)
• Comprehensive Analysis of Surgical Interventions for Musculoskeletal Disorders in Patients With Bleeding Disorders: Report From a Subspecialty Unit in a Developing Country (2025)
• Genetic and clinical characterization of factor VII deficiency: insights from 34 Turkish patients (2025)
• Rifampicin-Induced Toxic Hepatitis in a Patient with Hemophilia After Chemical Synovectomy (2024)
• Retrospective analysis of hemophilia B in Turkey: identifying main characteristics and treatment options (2024)
• Knee arthrodesis in treatment of haemophilic arthropathy of the knee (2024)
• A unique case of thrombophilia: the role of F9 gene duplication and increased factor IX activity in cerebral venous thrombosis (2023)
• Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial (2023)
• Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial (2023)
• Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency (2023)
• Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment. (2023)
• Effect of CTLA-4 and TNF-α Gene Polymorphisms on Inhibitor Development in a Turkish Cohort of Severe Hemophilia A Cases with Intron 22 Inversion Mutation: An Analytical Study (2022)
• LONG-TERM EFFECT OF TUROCTOCOG ALFA PEGOL ON TREATMENT SATISFACTION IN PREVIOUSLY TREATED PATIENTS WITH HAEMOPHILIA A: RESULTS FROM PATHFINDER8 (2022)
• Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors (2022)
• New Treatment Modalities in Hemophilia (2022)
• Gene therapy in haemophilia: literature review and regional perspectives for Turkey (2022)
• SURGERIES AND DIAGNOSTIC PROCEDURES IN HAEMOPHILIA PATIENTS ON CONCIZUMAB PROPHYLAXIS IN PHASE 2 CLINICAL TRIALS (2022)
• MANAGEMENT OF BREAKTHROUGH BLEEDS DURING CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A/B WITH AND WITHOUT INHIBITORS IN PHASE 3 CLINICAL TRIALS (2022)
• The value of ultrasonography in detecting early arthropathic changes and contribution to the clinical approach in patients of hemophilia. (2022)
• Kronik Myeloid Lösemide Tirozin Kinaz İnhibitörünün Kesilmesi Mümkün Mü? (2021)
• Plasma‐derived factor X concentrate compassionate use for hereditary factor X deficiency: Long‐term safety and efficacy in a retrospective data‐collection study (2021)
• Hemofilide Yeni Tedavi Seçeneklerinde Hasta ve Hasta Yakını Perspektifi (2021)
• ERGEN VE ERİŞKİN AĞIR HEMOFİLİ HASTALARININ EKLEM AĞRILARI NEDENİYLE ANALJEZİK KULLANIM ALIŞKANLIKLARINA YÖNELİK ANKET ÇALIŞMASI: ELDE EDİLEN ÇOK ÖNEMLİ SONUÇLAR İLE ÇIKARTILAN ÖNEMLİ DERSLER (2021)
• İKİ YILDAN FAZLA SÜREDİR RADİOİZOTOP SİNOVEKTOMİ UYGULAMASI YAPILMASINI BEKLEYEN HEDEF EKLEM VE KRONİK AKTİF SİNOVİTLİ HEMOFİLİ HASTALARINDA COX-2 İNHİBİTÖR ETKİLİ ORAL CELECOXİB UYGULAMASININ ARTROPATİYE OLAN ETKİLERİ (2021)
• Cost of hemophilia A in Turkey: an economic disease burden analysis (2021)
• Prophylaxis in children with haemophilia in an evolving treatment landscape (2021)
• LONGER-TERM EFFICACY AND SAFETY OF CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: RESULTS FROM THE EXTENSION PART OF THE PHASE 2 EXPLORER5 TRIAL (2021)
• Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency (2021)
• A Novel Molecular Indicator for Inhibitor Development in Haemophilia A (2021)
• Does Digital Templating of total knee arthroplasties reliable in hemophilic arthropathies? (2021)
• Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study (2021)
• Correlation between HJHS and HEAD- US Scores during Prophylaxis in Turkish Patients with Hemophilia: National Prospective Observational Study (2020)
• FIVE YEARS OF EXPERIENCE FOR TREATMENT REGIMENS OF PUP PATIENTS IN HEMOPHILIA-A PATIENTS: EXPERIENCE FROM EGE HEMOPHILIA CENTER (2020)
• CIRCUMCISION OPERATION WITHOUT USING BY-PASSING AGENTS IN PATIENT WITH HIGH RESPONDER INHIBITOR WHILE HE WAS IN WEEKLY EMICIZUMAB PROPHYLAXIS (2020)
• Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial (2020)
• Five years of experience for treatment regimens of PUP patients in Hemophilia-A: Experience from Ege Hemophilia Center. (2020)
• VON WİLLEBRAND HASTALIĞI’NDA VWF GENİ MUTASYON SPEKTRUMU (2020)
• Retrospective Evaluation of Childhood Cutaneous Mastocytosis Cases (2020)
• Evaluation of Bleeding Phenotype of Inherited Factor VII Deficiency in Children With a Bleeding Assessment Tool and Global Assays (2020)
• Turkey Experience in Molecular Analysis of Hemophilia B: F9 Gene Mutation Spectrum and Genotype-Phenotype Correlation (2020)
• A NOVEL MOLECULAR INDICATOR FOR INHIBITOR DEVELOPMENT IN HEMOPHILIA A (2020)
• Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa (2020)
• Factor 8 Gene Mutation Spectrum of 270 Patients with Hemophilia A: Identification of 36 Novel Mutations (2020)
• Simultaneous total hip and knee arthroplasties in hemophiliacs (2020)
• Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients (2020)
• Correlation between HJHS and HEAD-US Scores during Prophylaxis in Turkish Patients with Hemophilia: National Prospective Observational Study (2020)
• THE EFFECT OF SELF-INFUSION AND PATIENT EDUCATION ON TREATMENT COMPLIANCE IN HEMOPHILIA PATIENTS (2020)
• PHARMACOKINETIC-GUIDED PROPHYLAXIS BASED ON BAYESIAN MODEL WITH MYPKFIT (R) IN HEMOPHILIA A: TURKISH EXPERIENCE (2020)
• PgmNr 1155: A single center experience ın Turkey in the molecular diagnosis of hemophilia B. (2019)
• HEMOFİLİ B HASTALIĞI MOLEKÜLER ANALİZİNDE TÜRKİYE DENEYİMİ: F9 GEN MUTASYON SPEKTRUMU VE GENOTİP-FENOTİP İLİŞKİSİ (2019)
• İnhibitörlü Bir Olguda Faktör Yedekleme Davranışı (2019)
• Pharmacokinetic-guided prophylaxis based on bayesian model with myPKFiT (R) in hemophilia A: Turkish experience (2019)
• Pharmacokinetic-guided prophylaxis based on bayesian model with my PKFİT in hemophilia A: Turkish experience (2019)
• A single center experience in Turkey in the molecular diagnosis of Hemophilia B (2019)
• İnhibitörlü Pediatrik Hemofili Olgularında Faktör Kullanımı (2019)
• Çocuğu Hemofili Tedavisi Gören Anne-Babaların Acil Servis Deneyimleri (2019)
• Prospective Evaluation of Non-Compliant Severe Hemophilia Patients (2019)
• Extended Half-Life (EHL) Coagulation Factors: A New Era in the Management of Haemophilia Patients (2019)
• İnhibitörlü Hemofili Olgularında Yaşam Kalitesini Olumsuz Etkileyen Faktörler (2019)
• A single center experience in Turkey in the molecular diagnosis of Hemophilia B (2019)
• Impact of total knee arthroplasty for hemophilic arthropathy on patient-reported outcome measures (2019)
• Common themes and challenges in hemophilia care: a multinational perspective. (2019)
• Fertility in Patients with Thalassemia and Outcome of Pregnancies: A Turkish Experience (2019)
• International Laboratory Symposium Workshop On Coagulation Disorders/Uluslararası Pıhtılaşma Bozukluklarında Laboratuvar Sempozyum ve Çalıştayı Kitabı (2018)
• Hemofili Eğitimi Etkinliklerinin Değerlendirilmesi (2018)
• YEDİ HEMOFİLİ B HASTASINDA MUTASYON SPEKTRUMU VEGENOTİP-FENOTİP İLİŞKİSİ (2018)
• PgmNr 2869: Intragenic large deletions of F8 gene in Hemophilia A: Lessons from DNA sequencing analysis. (2018)
• HEMOPHILIA A HASTALARINDA F8 GEN MUTASYON SPEKTRUMU: 21 YENİ MUTASYON TANIMLAMASI (2018)
• İnhibitörlü Hemofili Olgularında Faktör Uygulama Zorlukları (2018)
• Concizumab exposure-response modeling in hemophilia A patients (2018)
• AĞIR HEMOFİLİ A OLGULARINDA YENİ NESİL DİZİ ANALİZİ İLE F8 GENİ BÜYÜK DELESYONLARININ BELİRLENMESİ (2018)
• Mutation spectrum of F8 gene in Turkish hemophilia A patients: identification of 14 novel mutations (2018)
• -AĞIR HEMOFİLİ A HASTALARINDA İNTRON 1 İNVERSİYONMUTASYONU SIKLIĞININ BELİRLENMESİ (2018)
• Is it possible ‘to forget the joint’ after total knee replacements in hemophiliacs? (2018)
• Hemofili olgularında ultrasonografi (HEAD-US) ve fizik muayene (HJHS) ile eklem sağlık durumunun karşılaştırılması. (2018)
• Hemofili Hastalarının Profilaktik Tedavisinin Eklem Sağlığına Olan Etkilerinin Takip Edilmesinde Ultrasonun Rolü: HEAD-US Skorlama Sistemi. (2018)
• Hemofili AHastalarında F8 Gen Mutasyon Spektrumu:21 Yeni Mutasyon Tanımlaması (2018)
• Mutation Spectrum of F8 gene in Turkish Hemophilia A Patients: Identification of 14 Novel Mutations (2018)
• Role of Arthroscopic Debridement of Hemophilic Ankles. (2018)
• HEMOFİLİ A HASTALARINDA F8 GEN MUTASYON SPEKTURUMU: 18 YENİ MUTASYON TANIMLANMASI (2018)
• Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial (2018)
• Burden of bleeds and other determinants on caregivers of children with moderate or severe haemophilia - Results of the BBC Study (2018)
• Use of high-purity factor X for on-demand treatment of bleeding episodes in factor X deficient patients: Results from a multicenter, retrospective, data collection study (2018)
• Mutation spectrum of F8 gene in Turkish hemophilia A patients: identification of 14 novel mutations (2018)
• Evaluation of the effect on endogenous factor VIII activity (FVIII: C) after recombinant von Willebrand factor (rVWF) administration during the elective surgery study in patients with severe von Willebrand disease (VWD) (2018)
• Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study (2018)
• The management of menorrhagia in Von Willebrand Disease: Single center experience (2018)
• Stevens-Johnson syndrome associated with methotrexate treatment for acute lymphoblastic leukemia: a case report (2018)
• Is it possible 'to forget the joint' after total knee replacements in hemophiliacs? (2018)
• HEMOFİLİ: ULUSAL TANI VE TEDAVİ KILAVUZU - 2017 (2017)
• A desensitization case of RecombinatFactorVIIa (2017)
• Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment (2017)
• Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series (2017)
• İnhibitörlü Bir Olguda Kanama Öyküsü (2017)
• The efficacy of arthroscopic debridement of ankle in patients with bleeding disorders (2017)
• TREATMENT OF A SUBDURAL HEMATOMA AND LONG-TERM SECONDARY PROHYLAXIS WITH FACTOR X. (2017)

Özgeçmiş